



Request for Quotation #2023-010

HCV Treatment Medication

I. Summary of Deadlines

Release of Request for Quotation	May 18, 2023
Quotations due	May 23, 2023
Bidders notified of decision	May 26, 2023

Note that PATH reserves the right to modify this schedule as needed. All parties will be notified simultaneously by email of any changes.

II. PATH Statement of Business

PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health. Learn more at www.path.org.

III. Purpose of RFQ

Project background:

Public health evidence and current gaps in HCV testing, diagnosis, linkage, and treatment are similar to the gaps and needs for HIV diagnosis, linkage, and treatment. This is the basis for the operations research agenda proposed for an additional output and work area through HIV Self-Testing Africa (STAR), a Unitaid-funded initiative that currently operates in 13 countries and aims to catalyze the global market for HIVST, generate evidence, and create an enabling environment for scale-up. Through the HIV Self-Testing Africa consortium, PATH will conduct implementation research to assess different HCVST delivery models in two HIV Self-Testing Africa countries—India and Vietnam—which have high HCV disease burden and diagnostic gaps among KPs and PLHIV.

In Vietnam, this research study aims to evaluate the relative effectiveness of three types of HCVST models in reaching first time HCV testers as compared to routine provider-led testing among KP, PLHIV, and their sexual and/or injecting partners, in order to support attainment of the country’s viral hepatitis elimination goals and inform key national and global guidelines and best practices for HCVST and HCV service delivery. The study involves the use of HCV self-tests which are not currently authorized/licensed in the country. Clients who have positive HCVST results will be referred to other sites for further

confirmatory testing and treatment services where clients receive HCV treatment medications purchased from this study.

Purpose of the RFQ: **PATH seeks to obtain price of the products needed as in details below:**

A. Products: HCV treatment medication

1. Sofosbuvir 400mg:
2. Daclatasvir 60mg (Daclatasvir dihydrochloride)

B. Quantity:

- **Option 1:**

900 boxes of Sofosbuvir 400mg, each box contains 28 tablets or equivalent total tablets if the packaging is different.

900 boxes of Daclatasvir 60mg, each box contains 28 tablets or equivalent total tablets if the packaging is different.

- **Option 2:**

1,500 boxes of Sofosbuvir 400mg, each box contains 28 tablets or equivalent total tablets if the packaging is different.

1,500 boxes of Daclatasvir 60mg, each box contains 28 tablets or equivalent total tablets if the packaging is different.

C. Delivery:

- **Option 1:** If the purchase order is 900 boxes for each medication (Sofosbuvir 400mg and Daclatasvir 60mg), the products will be delivered twice to two clinics (1 in Hanoi, 1 in Ho Chi Minh City). Tentatively, each clinic in Hanoi and Ho Chi Minh City will receive 450 boxes of treatment medication.
- **Option 2:** If the purchase order is 1,500 boxes for each medication (Sofosbuvir 400mg and Daclatasvir 60mg), the products will be delivered to three clinics (1 in Hanoi, 1 in Ho Chi Minh City and 1 in Nghe An). Tentatively, each clinic in Hanoi and Ho Chi Minh City will receive 705 boxes of each medication, and clinic in Nghe An will receive 45 boxes of each medication.

D. Additional Requirement:

- Expiration date: At least 12-18 months from the time of receipt.
- All taxes and fees applicable should be included in the quotation.
- All procedures to distribute the products in Vietnam will be handled by the vendor.
- The product should be door-to-door delivered.
- Delivery location: Hanoi, Ho Chi minh City and/or Nghe An

IV. Proposal Requirements

Provide itemized costs for the products. Bids should include itemized costs for key elements of the scope of work, as follows:

- Cost of products

- Any other associated costs
- Payment terms
- Warranty
- Expiration date
- Delivery time

Provide information on your overall qualifications, including:

- Profile of relevant corporate business license.
- Profile of relevant experience and examples of related work.
- If your company has more than one location, please indicate these qualifications for the site that is responding.

V. Instructions for Responding.

A. PATH contacts

Technical/Program Contact:

- Mr. Vu Ngoc Bao, Senior Technical Advisor, email: bvu@path.org
- Mr. Do Tuan Kim, Project Manager: email: kdo@path.org

Procurement Contact:

- Mr. Tran Minh Dung, Project Administrator, email: dtran@path.org
- Ms. Nguyen Thuc Hang, Procurement Associate, email: htnguyen@path.org

B. Quotations due: 5:00PM ICT, May 23, 2023

Completed quotations should be submitted by email to the contacts listed above. The subject line of the email should read: RFQ 2023-010 – Your Company Name.

C. Conclusion of process

Applicants will be notified of PATH’s decision by **May 26, 2023**. Final award is subject to the terms and conditions included in this solicitation, as well as successful final negotiations of all applicable terms and conditions affecting this work.

VI. Terms and Conditions of the Solicitation

A. Notice of non-binding solicitation

PATH reserves the right to reject any and all bids received in response to this solicitation and is in no way bound to accept any proposal.

B. Confidentiality

All information provided by PATH as part of this solicitation must be treated as confidential. In the event that any information is inappropriately released, PATH will seek appropriate remedies as allowed.

Proposals, discussions, and all information received in response to this solicitation will be held as strictly confidential, except as otherwise noted.

C. Conflict of interest disclosure

Suppliers bidding on PATH business must disclose, to the procurement contact listed in the RFP, any actual or potential conflicts of interest. Conflicts of interest could be present if; there is a personal relationship with a PATH staff member that constitutes a significant financial interest, board memberships, other employment, and ownership or rights in intellectual property that may be in conflict with the supplier's obligations to PATH. Suppliers and PATH are protected when actual or perceived conflicts of interest are disclosed. When necessary, PATH will create a management plan that provides mitigation of potential risks presented by the disclosed conflict of interest. All communications regarding this solicitation shall be directed to appropriate parties at PATH indicated in Section VIII. A. Contacting third parties involved in the project, the review panel, or any other party may be considered a conflict of interest and could result in disqualification of the proposal.

D. Acceptance

Acceptance of a proposal does not imply acceptance of its terms and conditions. PATH reserves the option to negotiate on the final terms and conditions. We additionally reserve the right to negotiate the substance of the finalists' proposals, as well as the option of accepting partial components of a proposal if appropriate.

E. Proposal Validity

Proposals submitted under this request shall be valid for 90 days from the date the proposal is due. The validity period shall be stated in the proposal submitted to PATH.